Lum, Bert
3 papers on CoChat
Most cited papers
- Verified
Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I–III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial
Ismael, G., Hegg, R., Muehlbauer, S., Heinzmann, D., Lum, B., Kim, S.-B., Pienkowski, T., Lichinitser, M., Semiglazov, V., Melichar, B., et al. (2012) · The Lancet Oncology
HER2/EGFR in Cancer ResearchGastric Cancer Management and Outcomes
Cited by 351
- Verified
Subcutaneous versus intravenous formulation of trastuzumab for HER2-positive early breast cancer: updated results from the phase III HannaH study
Jackisch, C., Kim, S.-B., Semiglazov, V., Melichar, B., Pivot, X., Hillenbach, C., Stroyakovskiy, D., Lum, B. L., Elliott, R., Weber, H. A., et al. (2015) · Annals of Oncology
HER2/EGFR in Cancer ResearchGastric Cancer Management and Outcomes
Cited by 114
- Verified
Use of a Population Pharmacokinetic Approach for the Clinical Development of a Fixed‐Dose Subcutaneous Formulation of Trastuzumab
Hourcade‐Potelleret, F., Lemenuel‐Diot, A., McIntyre, C., Brewster, M., Lum, B., & Bittner, B. (2014) · CPT: Pharmacometrics & Systems Pharmacology
Pharmaceutical studies and practicesHER2/EGFR in Cancer Research
Cited by 28
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free